INSTRUCTIONS

1. **Author groups**: Please check that all names have been spelled correctly and appear in the correct order. Please also check that all initials are present. Please check that the author surnames (family name) have been correctly identified by a pink background. If this is incorrect, please identify the full surname of the relevant authors. Occasionally, the distinction between surnames and forenames can be ambiguous, and this is to ensure that the authors' full surnames and forenames are tagged correctly, for accurate indexing online. Please also check all author affiliations.

2. **Figures**: If applicable figures have been placed as close as possible to their first citation. Please check that they are complete and that the correct figure legend is present. Figures in the proof are low resolution versions that will be replaced with high resolution versions when the journal is printed.

3. **Missing elements**: Please check that the text is complete and that all figures, tables and their legends are included.

4. **Special characters**: Please check that special characters, equations, dosages and units, if applicable, have been reproduced accurately.

5. **Funding**: Please provide a Funding statement, detailing any funding received. Remember that any funding used while completing this work should be highlighted in a separate Funding section. Please ensure that you use the full official name of the funding body, and if your paper has received funding from any institution, such as NIH, please inform us of the grant number to go into the funding section. We use the institution names to tag NIH-funded articles so they are deposited at PMC. If we already have this information, we will have tagged it and it will appear as coloured text in the funding paragraph. Please check the information is correct.
The following queries have arisen during the typesetting of your manuscript. Please answer these queries by marking the required corrections at the appropriate point in the text.

<table>
<thead>
<tr>
<th>Query No.</th>
<th>Nature of Query</th>
<th>Author's Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>Please check that all names have been spelled correctly and appear in the correct order. Please also check that all initials are present. Please check that the author surnames (family name) have been correctly identified by a pink background. If this is incorrect, please identify the full surname of the relevant authors. Occasionally, the distinction between surnames and forenames can be ambiguous, and this is to ensure that the authors’ full surnames and forenames are tagged correctly, for accurate indexing online. Please also check all author affiliations.</td>
<td></td>
</tr>
<tr>
<td>Q2</td>
<td>Details given in references [35] and [108] were same. Hence, reference [108] has been deleted and the references have been renumbered accordingly.</td>
<td></td>
</tr>
<tr>
<td>Q3</td>
<td>Details given in references [73] and [119] were same. Hence, reference [119] has been deleted and the references have been renumbered accordingly.</td>
<td></td>
</tr>
<tr>
<td>Q4</td>
<td>Please check the in-text citation of Table 2.</td>
<td></td>
</tr>
<tr>
<td>Q5</td>
<td>Please provide author name for ‘unpublished data’.</td>
<td></td>
</tr>
<tr>
<td>Q6</td>
<td>If references has more than 3 authors, then list the names of first 3 authors followed by et al.; otherwise, provide the names of all the authors.</td>
<td></td>
</tr>
<tr>
<td>Q7</td>
<td>Please provide the volume number and page range for ref [83].</td>
<td></td>
</tr>
<tr>
<td>Q8</td>
<td>Please update ref [111] and [121].</td>
<td></td>
</tr>
<tr>
<td>Q9</td>
<td>Please provide the year of publication for ref [123].</td>
<td></td>
</tr>
</tbody>
</table>
MAKING CORRECTIONS TO YOUR PROOF

These instructions show you how to mark changes or add notes to the document using the Adobe Acrobat Professional version 7.0 (or onwards) or Adobe Reader 8 (or onwards). To check what version you are using go to Help then About. The latest version of Adobe Reader is available for free from get.adobe.com/reader.

For additional help please use the Help function or, if you have Adobe Acrobat Professional 7.0 (or onwards), go to http://www.adobe.com/education/pdf/acrobat_curriculum7/acrobat7_lesson04.pdf.

Displaying the toolbars

Adobe Reader 8: Select Tools, Comments & Markup, Show Comments and Markup Toolbar. If this option is not available, please let me know so that I can enable it for you.

Acrobat Professional 7: Select Tools, Commenting, Show Commenting Toolbar.

Adobe Reader 10: To edit the galley proofs, use the Comment Toolbar (Sticky Note and Highlight Text).

Using Text Edits

This is the quickest, simplest and easiest method both to make corrections, and for your corrections to be transferred and checked.

1. Click Text Edits
2. Select the text to be annotated or place your cursor at the insertion point.
3. Click the Text Edits drop down arrow and select the required action.

You can also right click on selected text for a range of commenting options.

Pop up Notes

With Text Edits and other markup, it is possible to add notes. In some cases (e.g. inserting or replacing text), a pop-up note is displayed automatically.

To display the pop-up note for other markup, right click on the annotation on the document and selecting Open Pop-Up Note.

To move a note, click and drag on the title area.

To resize of the note, click and drag on the bottom right corner.

To close the note, click on the cross in the top right hand corner.

To delete an edit, right click on it and select Delete. The edit and associated note will be removed.

SAVING COMMENTS

In order to save your comments and notes, you need to save the file (File, Save) when you close the document. A full list of the comments and edits you have made can be viewed by clicking on the Comments tab in the bottom-left-hand corner of the PDF.
Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody Tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review we will outline the biology surrounding IL-6 and will discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6 blocking therapies in renal disease.

**Keywords:** cytokines, interleukin-6, renal disease, therapy

**ABSTRACT**

Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody Tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review we will outline the biology surrounding IL-6 and will discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6 blocking therapies in renal disease.

**Keywords:** cytokines, interleukin-6, renal disease, therapy

**INTRODUCTION**

Cytokines perform pivotal roles during infection, trauma, cancer and inflammation where they control cellular proliferation, differentiation, survival or death and cytokine specific gene expression. Here, cytokine-driven communication between immune cells and stromal non-haematopoietic cells enables resolution of the condition and is part of the healing process [1]. However during chronic inflammatory conditions, appropriate regulation of the immune response is lost and drives disease progression. Under these circumstances, cytokines affect the development of autoimmunity, chronic inflammation and deleterious tissue damage [1]. This has ultimately led to the design of biologic drug agents that target specific cytokines to prevent the rapid clinical progression of disease. For example, tumour necrosis factor-α (TNFα) blockers (e.g. the neutralizing anti-TNFα antibodies Infliximab, Adalimumab, Golimumab, Certolizumab or the soluble TNF-R2 Fc-fusion protein Etanercept) are broadly used to treat various autoimmune conditions, while interleukin (IL)-1β inhibitors (e.g. the IL-1 receptor antagonist, Anakinra) have shown robust efficacy in auto-inflammatory conditions [2]. Although these agents are effective treatments for many diseases, not all biologics work in all patients, and not all biologics work in all inflammatory conditions [1, 2]. Such observations are significantly influencing the way researchers consider cytokine involvement in disease. Emphasis is now placed on identifying alternative cytokine targets and strategies for therapeutic intervention, while a greater attention to cytokine biology and signalling is providing opportunities to stratify patients with chronic disease for more appropriate treatment. Here, research is leading to a detailed understanding of how the cytokine network becomes distorted to drive chronic inflammation instead of competent host defense. During the course of this review, we discuss the impact of IL-6 in renal disease and will describe aspects of its biology that affect disease onset and progression, prognosis and treatment decisions.
most highly regulated mediators of inflammation (increasing from 1–5 pg/mL to several μg/mL in certain conditions) and performs central roles in infection, autoimmunity and cancer [6–9]. While traditionally viewed as a downstream target of TNFα and IL-1β activity, various other inflammatory stimuli induce IL-6 expression, and IL-6 forms part of an integrated cytokine network that controls innate and adaptive immunity [3, 8, 9]. As a consequence, IL-6 is a major target for therapeutic intervention and the complex nature of its biology has led to development of various therapies that target either the cytokine directly (e.g. Olokizumab, Clazakizumab) or the α-subunit of its receptor (e.g. Tocilizumab, Sarilumab) [9]. A full list of blocking IL-6 strategies and the current status of their clinical development is shown in Table 1. This information covers specific IL-6 targeting agents and small molecule inhibitors that block intracellular proteins associated with (but not necessary exclusive to) IL-6 receptor signalling. Given that cytokines, such as IL-6 contribute to the progression of renal disease and associated complications (e.g. vascular calcification, wasting, fatigue and cardiovascular risk), the potential applications of anti-cytokine targeted intervention deserves closer attention [16, 17]. For additional information on IL-6 targeted therapies the reader is directed elsewhere [2, 9, 18].

The IL-6 receptor complex consists of an 80 kDa cognate receptor (IL-6R, CD126) and a 130 kDa signal-transducing element (gp130, CD130) [8, 9]. Although IL-6R is largely confined to hepatocytes, certain leukocytes and some epithelial lining cells, IL-6 activity is also controlled by a naturally occurring soluble IL-6R (sIL-6R). The sIL-6R is a key regulator of IL-6 responses and forms a sIL-6R/IL-6 complex capable of activating cells via the ubiquitously expressed gp130 [3, 7–9, 19]. This process is called IL-6 trans-signalling, and activates IL-6-type responses in cells lacking IL-6R (e.g. vascular endothelial cells, peritoneal mesothelial cells and synovial fibroblasts). Interleukin-6 responses in vivo are therefore mediated by IL-6 activation of a membrane-bound IL-6R (classical IL-6R signalling) or via its soluble receptor (Figure 1). In both cases, IL-6 activates gp130 associated cytoplasmic tyrosine kinases (Janus kinases; Jak1, Jak2 and Tyk2), which control the latent transcription factors STAT1 and STAT3, and signalling through the Ras–Raf cascade. For a more detailed overview of IL-6 signalling the reader is directed elsewhere [20].

From a clinical perspective, measurements of IL-6, its soluble receptor and indices of IL-6 bioactivity (e.g. STAT3 responses) are increasingly viewed as surrogate markers of inflammation, disease severity and valuable predictors of disease progression. During the course of this review we will consider the impact of IL-6 biology in various aspects of renal disease, transplantation and therapy and detail potential avenues for future clinical translation (Table 1).

**CONTROL OF IL-6 EXPRESSION BY INFLAMMATION, GENETIC VARIATION AND MICRORNAS**

In chronic inflammation and autoimmunity IL-6 plays roles in both local (e.g. control of chemokine-directed leukocyte recruitment) and systemic inflammation (e.g. activation of the acute phase response). Here, IL-6 transcription is regulated by various pro-inflammatory cytokines and growth factors (e.g. IL-1, TNFα and platelet derived growth factor; PDGF), increases in intracellular cyclic AMP and certain pattern recognition receptors following activation by microbial or endogenous ligands [1]. Interleukin-6 is rapidly expressed in a highly transient manner during inflammation. Here, circulating sIL-6R concentrations act as a buffering system that helps to maintain the circulating half-life of IL-6. Thus, sIL-6R is a central regulator of IL-6 bioactivity and must be tightly controlled to limit overt IL-6 signalling (Figure 1). While circulating levels of soluble gp130 (sgp130) selectively antagonize IL-6 trans-signalling, intracellular regulators of IL-6R-gp130 signalling (e.g. suppressor of cytokine signalling; SOCS proteins) prevent a prolonged activation by IL-6. Of equal importance are genetic factors, which substantially influence IL6 expression. This is best illustrated by the identification of functional polymorphisms within the IL6 promoter. For example, a G > C (rs1800795) mutation found at position −174 bp upstream from the transcriptional start site leads to enhanced IL-6 expression [21]. Similar genetic variations up to 6 kb from the start of transcription also correlate with serum and constitutive IL-6 levels. Patients displaying the rs1800795 mutation often show increased susceptibility to coronary artery disease, juvenile idiopathic arthritis and many other conditions typified by chronic inflammation or autoimmunity. Similar genetic mutations also occur in the IL6R loci, with the rs2228145 variant affecting the proteolytic release of sIL-6R from cells. Significantly, the rs2228145 mutation in various ethnic populations has been linked to insulin resistance, an increase in body mass index, Type-II diabetes and diabetic nephropathy [22–28].

Recent data show that microRNAs also govern IL-6 expression and activity. MicroRNAs are short endogenous RNA regulators of gene expression, the first of which was identified in the nematode Caenorhabditis elegans in 1993 [29]. MicroRNAs are present in all human cells, and each represses the expression of a specific set of genes. The let-7 family contains the first microRNAs to be identified in mammals [30]. Let-7 microRNAs, most notably let-7a, target and repress synthesis of IL-6 [31]. Let-7 microRNAs are themselves down-regulated by Lin28B [31], which is induced following activation of nuclear factor-κB (NF-κB) to ensure optimal Il6 expression and cellular transformation [32]. Also, microRNA-23a targets and represses Il6r [33], meaning that cellular capacity to respond to IL-6 is also microRNA-regulated. MicroRNAs are also important effectors of IL-6 responses. For example, microRNAs-21 and microRNAs-181b–1 are induced by IL-6 activation of Stat3. These increase NF-κB activity via repression of their targets phosphatase and tensin homologue (PTEN) and CYLD (the human gene associated with cylindromatosis) [34]. Finally, emerging data show that microRNAs may be released by cells, and serve as a mechanism for intercellular communication. A subset of these extracellular microRNAs can induce pro-inflammatory responses, including IL-6 secretion, by binding to and activating Toll-Like Receptors [35].

**Q2**
<table>
<thead>
<tr>
<th>Targeting Strategy</th>
<th>Compound</th>
<th>Company</th>
<th>Specificity</th>
<th>Disease</th>
<th>Phase</th>
<th>ClinicalTrials.gov</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global IL-6 signaling</td>
<td>Tocilizumab (ACTEMRA, RoACTEMRA)</td>
<td>Chugai, Roche</td>
<td>Humanized IL-6 receptor-specific mAb</td>
<td>Castlemann’s disease</td>
<td>2005, Japan</td>
<td>Approved</td>
</tr>
<tr>
<td>Targeting soluble and membrane-bound</td>
<td></td>
<td></td>
<td></td>
<td>Juvenile idiopathic arthritis</td>
<td>2008, Japan</td>
<td>Approved</td>
</tr>
<tr>
<td>Interleukin 6 receptor</td>
<td></td>
<td></td>
<td></td>
<td>Systemic-onset juvenile idiopathic arthritis</td>
<td>2008, Japan</td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rheumatoid Arthritis</td>
<td>2009, EMEA; 2010, FDA</td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adult’s still disease</td>
<td>Phase II; 2009–11</td>
<td>NCT01002781</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Graves’ ophthalmopathy</td>
<td>Phase II; 2010–12</td>
<td>NCT01104480</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Relapsing polychondritis</td>
<td>Phase III; 2010–14</td>
<td>NCT01209702</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ankylosing spondylitis</td>
<td>2010–12</td>
<td>NCT01073826</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Type II diabetes and exercise</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>REGN88 (SAR153191)</td>
<td>Regeneron/Sanofi-Aventis</td>
<td>Fully human IL-6 receptor-specific mAb</td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2010–12</td>
<td>NCT01217814</td>
</tr>
<tr>
<td></td>
<td>ALX-0061 (Olokizumab)</td>
<td>Ablynx</td>
<td>IL-6 receptor-specific VHH</td>
<td>Rheumatoid arthritis</td>
<td>Phase II + III; 2010–13</td>
<td>NCT01061736</td>
</tr>
<tr>
<td></td>
<td>CNT0136 (Sirukumab)</td>
<td>Centocor, Inc.,</td>
<td>Fully human IL-6-specific mAb</td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2010–15</td>
<td>NCT01146652</td>
</tr>
<tr>
<td></td>
<td>CNT0328 (cCLB, Siltuximab)</td>
<td>Centocor, Inc.,</td>
<td>Chimeric IL-6-specific mAb</td>
<td>Rheumatoid arthritis</td>
<td>Phase I; 2008–11</td>
<td>NCT00718718</td>
</tr>
<tr>
<td></td>
<td>ALD518 (BMS-945429)</td>
<td>Alder Biopharm./Bristol-Myers</td>
<td>Humanized IL-6-specific mAb, aglycosylated</td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2006–12</td>
<td>NCT01024036</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Squibb</td>
<td></td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2009–14</td>
<td>NCT00911859</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Multiple myeloma [125]</td>
<td>Phase II; 2010–14</td>
<td>NCT01266811</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prostate cancer</td>
<td>Phase I; 2005–10</td>
<td>NCT00401765</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2006–08</td>
<td>NCT00385827</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2007–09</td>
<td>NCT00433446</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2008–11</td>
<td>NCT00718718</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2006–12</td>
<td>NCT01024036</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2009–14</td>
<td>NCT00911859</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2010–14</td>
<td>NCT01266811</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2008–09</td>
<td>NCT00866970</td>
</tr>
<tr>
<td>IL-6 Trans-signaling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeting IL-6/sIL-6R</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Downstream signaling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeting janus kinases (JAKs)</td>
<td>Tofacitinib</td>
<td>Pfizer</td>
<td>JAK1 and 2</td>
<td>Rheumatoid arthritis</td>
<td>Phase III; 2013</td>
<td>NCT00661661</td>
</tr>
<tr>
<td>downstream of gp130/IL6ST</td>
<td></td>
<td></td>
<td></td>
<td>Kidney transplant</td>
<td>Phase II; 2006</td>
<td>NCT00106639</td>
</tr>
<tr>
<td></td>
<td>Ruxolitinib</td>
<td>Incyte/Novartis</td>
<td>JAK1 and 2</td>
<td>Rheumatoid arthritis</td>
<td>Phase I–III; 2004–14</td>
<td>NCT01519089</td>
</tr>
<tr>
<td></td>
<td>Baricitinib</td>
<td>Eli Lilly/Incyte</td>
<td>JAK1 and 2</td>
<td>Multiple myeloma</td>
<td>Phase II; 2010</td>
<td>NCT00639002</td>
</tr>
<tr>
<td>(INCB-28050)</td>
<td>GLPG-0634</td>
<td>Abbot/Galapagos</td>
<td>JAK1</td>
<td>Myelofibrosis</td>
<td>Phase II; 2012–13</td>
<td>NCT01340651</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Plaque psoriasis</td>
<td>Phase II; 2009</td>
<td>NCT00820950</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II; 2010</td>
<td>NCT00902486</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase I–II; 2011–12</td>
<td>NCT01384222</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NCT01668641</td>
</tr>
<tr>
<td></td>
<td>AC430</td>
<td>Ambit Biosciences</td>
<td>JAK2</td>
<td>Rheumatoid arthritis</td>
<td>Phase I, 2011</td>
<td>NCT01287858</td>
</tr>
</tbody>
</table>
Clinical and experimental studies suggest that IL-6 contribute to renal injury in glomerulonephritis and other forms of renal disease. For example, elevated IL-6 expression in kidneys and urine of patients with mesangial proliferative glomerulonephritis is often associated with poor outcome [36]. In this context, IL-6 induces mesangial cell proliferation [36]. In murine models of lupus nephritis IL-6 activities promote tissue damage and disease severity [37–39], while transgenic mice displaying elevated levels of circulating IL-6 develop proteinuric nephropathy that culminates in death from renal failure [40]. Ultimately, the role of IL-6 in these conditions may relate to IL-6 involvement in fibrosis and tissue damage. In models of angiotensin-II induced renal disease, infusion of angiotensin-II induces IL-6 expression and renal fibrosis. This response is IL-6 dependent and IL-6-deficient mice remain resistant to renal injury [41]. Mechanistically, IL-6 may contribute to renal disease by enhancing the signalling response of tubular epithelial cells to pro-fibrotic cytokines such as transforming growth factor-β (TGFβ) [42]. However, data from other experimental models of renal injury show that IL-6 is not always a key facet of progressive kidney damage [43–45]. What factors contribute to these differences in disease outcome remain to be established, but may reflect differences in disease induction methods or protocols using cytokine-deficient animals versus direct manipulation of cytokine activity in wild type strains.

In patients with acute kidney injury (AKI), high circulating levels of IL-6 are predictive of increased mortality [10]. This outcome is also seen in murine models of ischaemia reperfusion injury- and nephrotoxin-induced models of AKI [11, 46, 47]. In mercuric chloride-induced AKI, IL-6 deficient mice exhibit less kidney-associated inflammation, and have improved outcome [47]. In the same study, IL-6 trans-signalling in tubular epithelial cells ameliorated injury and led to preservation of renal function. This led the authors to conclude that IL-6 simultaneously promotes an injurious inflammatory response and, through a mechanism involving IL-6 trans-signalling, protects the kidney from further injury [47]. These studies are akin to the role of IL-6 and IL-6 trans-signalling in regulating homeostatic gut epithelia remodelling versus colitis-like inflammation [9]. Significantly, tocilizumab is not prescribed in patients with a history of diverticulitis [2, 9].

Biologics against IL-6 are highly effective in autoimmune conditions including rheumatoid arthritis [1, 2]. To date, there is little data relating to IL-6 blockade in patients with renal...
Renal transplantation is considered to be the 'gold standard' treatment for most patients with end stage renal failure. Benefits include improved patient survival, quality of life and healthcare cost [53]. Recent advances in treatment means that the rate of acute clinical rejection (AR) has fallen. However, AR remains a determining factor for the development of chronic rejection and long-term allograft survival [53, 54].

Interleukin-6 has long been highlighted as a pro-inflammatory cytokine associated with renal allograft rejection. While IL-6 levels are low in the serum and urine of healthy individuals, renal transplant recipients display high serum and urinary IL-6 levels immediately post transplantation and during AR [55, 56]. For example, increased IL-6 mRNA transcripts have been identified in renal biopsies from patients undergoing AR [57]. Notably, while AR episodes have been associated with increased serum and urine IL-6 levels, preventative rejection treatments stabilize IL-6 expression and return them to baseline [12, 58].

Most studies have underlined the greater sensitivity of urinary IL-6, over serum measurements, as potential indicators of rejection. For example urinary actin, IL-6 and CXC-chemokine ligand 8 (CXCL8) have been proposed as biomarkers of sustained acute renal failure in allograft recipients [59]. Kwon et al. [59] observed elevated urinary IL-6 excretion in patients displaying sustained acute renal failure compared with those that went on to recover. For patients showing sustained failure, urinary IL-6 was increased on the day of transplant and also remained higher at postoperative Day 5. In a recent analysis of 90 transplant patients, stable allograft recipients showed similar levels of serum IL-6 to healthy individuals. However patients undergoing allograft rejection displayed significant increases in circulating IL-6 [60]. Notably, higher IL-6 levels were observed in individuals undergoing chronic allograft rejection compared with patients in AR [60]. Interestingly, while increases in serum and urinary IL-6 are associated with AR, sIL-6R levels do not correlate with rejection [12]. While the mechanisms affecting these outcomes are far from clear, they may relate to associated genetic factors. Meta-analysis of transplant patients shows that alterations in AR risk are associated with individuals bearing the rs1800795 ‘high’ IL-6 producing loci [61, 62]. Notably, in allogenic haematopoietic cell transplantation, the rs1800795 variant is linked with increased risk of developing acute graft-versus-host disease [62]. Therefore, IL-6 donor genotype may be more important in graft rejection than recipient genotype. Here, IL-6 may serve as an immune ‘danger signal’ thereby disrupting allograft tolerance.

Mechanisms underpinning the role of IL-6 in allograft transplant rejection may hinge on its partnership with TGFβ, which together balance the induction of T-cell tolerance versus pro-inflammatory effector responses. Regulatory T-cells (T_{reg}) provide tolerance by suppression of allo- and auto-immune responses [63–65]. These cells are defined by their expression of transcription factor FoxP3, and are either thymus derived (natural T_{reg}; nT_{reg}) or can differentiate from naïve CD4\(^+\) T-cells activated in the presence of TGFβ (induced T_{reg}; iT_{reg}) [66]. Such has been the impact of T_{reg} cells on allograft tolerance in experimental animal models, that recent studies have proposed FoxP3 as a prognostic marker for renal allograft outcome (see review [67]). Interestingly, IL-6 inhibits the TGFβ-mediated differentiation of iT_{reg} cells, instead favouring the development of IL-17-producing CD4\(^+\) T-cells (T_{h}17 cells) [68, 69]. While T_{reg} cells provide tolerance, there is mounting evidence of a role for T_{h}17 cells in allograft rejection. For example, allograft infiltrating T_{h}17 cells were associated with hallmarks of chronic rejection including exacerbated vasculopathy and fibrosis in models of cardiac allograft rejection [70, 71]. In renal allografts, elevated IL-17 mRNA and protein has been demonstrated during AR in both clinical patients and experimental models [72–74]. Owing to the bias of IL-6 for inducing effector T_{h}17 cells rather than regulatory T_{reg} populations with tolerogenic properties in allogenic grafts, therapeutically targeting the IL-6 signalling pathway may prove beneficial to renal transplant outcomes in patients undergoing acute and chronic rejection.

Haemodialysis (HD) and peritoneal dialysis (PD) represent the two major renal replacement therapies available for patients with end-stage renal disease (ESRD). Both IL-6 and sIL-6R are considered important prognostic markers of clinical outcome in ESRD patients. ESRD patients have elevated serum IL-6 levels prior to treatment [75, 76]. Impaired excretion due to reduced kidney function has been suggested as one reason for this elevation [77], although IL-6 mRNA is increased in the peripheral blood mononuclear cells of ESRD patients [78]. PD treatment itself leads to increases in systemic and intraperitoneal IL-6 and sIL-6R levels [79]. Here, systemic elevations in circulating levels may reflect a consequence of persistent or episodic bursts of inflammation, patient comorbidities, genetic factors, obesity, alterations in metabolism, infection incidence or other immunological events [80, 81]. However, raised serum IL-6 and sIL-6R levels at the beginning of treatment remain powerful predictors of mortality in both HD and PD patients [17, 75, 82, 83]. These changes may reflect the systemic inflammatory status of a patient, and often corresponds to elevations in C-reactive protein [83, 84]. For example, high IL-6 levels contribute to dialysis associated malnutrition [13, 14] and are prognostic of cardiovascular risk.
[85], which is an adverse outcome of haemodialysis [15]. Here, systemic elevations in IL-6 likely arise from the liver, muscle and the inflammatory activation of stromal tissues or myeloid cells (Table 2).

Patients receiving PD often experience a number of clinical complications. These include: (i) susceptibility to recurrent episodes of peritonitis and (ii) changes in the structure of the peritoneal membrane resulting in loss of ultrafiltration capacity and treatment failure. PD-associated peritonitis is caused predominantly by Gram-positive Staphylococcus species (most commonly by Staphylococcus epidermis and Staphylococcus aureus), but also by Gram-negative bacteria (e.g. Escherichia coli) and fungi (e.g. Candida albicans) [86]. Here, IL-6 is essential for the appropriate control of acute inflammation and promotes bacterial clearance. Murine models of peritonitis have shown IL-6/sIL-6R signalling via STAT3 regulates leukocyte recruitment and activation [87–91], and IL-6-deficient mice are less able to clear a number of bacterial species [4, 92] (unpublished data). Interestingly, individuals with defects in IL-6 or STAT3 display an impaired immune defense against Staphylococcal infection [93, 94], implying IL-6 is an essential part of the immune response to Staphylococcus species. Under these conditions, IL-6 is highly expressed by resident peritoneal leukocytes and mesothelial cells following microbial sensing by pattern recognition receptors [95–98]. Indeed elevated concentrations of IL-6 and sIL-6R are present in peritoneal dialysis effluent of patients during acute episodes of bacterial peritonitis [88].

Extended PD therapy is associated with functional and morphologic alterations to the peritoneal membrane and result in PD treatment failure [99]. These changes may be induced by uraemia, hyperglycaemia, prolonged exposure to bio-incompatible peritoneal dialysis fluids, age and recurrent episodes of peritonitis. Here, vascular alterations contribute to increased peritoneal solute transport [100]. IL-6 levels are also an important determinate of solute transport in PD [101]. Intrapерitoneal IL-6 and sIL-6R levels significantly correlate with the baseline peritoneal solute transport (PSTR) observed in PD patients and are predictive of pro-angiogenic factors present in the dialysate (CCL2; CC-chemokine ligand 2 and VEGF; vascular endothelial growth factor) [102]. In this regard, plasma levels of IL-6 and VEGF are associated with a high PSTR [17]. Again, the rs1800795 genetic loci relate to intraperitoneal IL-6 levels and baseline PSTR [103], and represent an independent risk factor for mortality and treatment failure [104]. Regarding the role of IL-6 in fibrotic changes, IL-6 plays a clear role in normal wound healing [105] and fibrogenesis in various organs (e.g. lung, skin and kidney) [41, 106, 107]. Recently, we have found that IL-6 is essential for the development of peritoneal fibrosis following recurrent peritonitis in a murine model [108]. IL-6-dependent changes in peritoneal Th1 responses and IFN-γ and STAT1 activation within the peritoneal membrane lead to alterations in the balance of matrix metalloproteinase to tissue inhibitors of matrix metalloproteinases. Collectively, these studies demonstrate a fundamental aspect of IL-6 involvement in inflammation and specifically emphasize its importance in governing the balance between provision of competent host defense and inflammation-induced tissue injury.

### INTERLEUKIN-6, COMORBIDITIES ANDURAEMIA IN END-STAGE RENAL DISEASE

Considerable emphasis has been placed on the relationship between IL-6 (and to a lesser extent sIL-6R) and C-reactive protein, cardiovascular risk and patient outcomes such as fatigue. However IL-6 also functions as a homeostatic regulator of catabolism, iron uptake and muscle wasting. The IL-6 control of these processes has a major bearing on patients with ESRD and affects the incidence of anaemia, protein-energy wasting and muscle atrophy [16, 109–113]. For example, the hepatic control of hepcidin expression in response to systemic elevations in IL-6 disrupts iron homeostasis and leads to iron-restricted erythropoiesis and anaemia [114–116]. In patients with rheumatoid arthritis, treatment with the blocking anti-IL-6R monoclonal antibody tocilizumab rapidly improves anaemia by reducing serum hepcidin [117]. In ESRD many of these processes are ultimately influenced by underlining alterations in uraemia. Studies show that uraemia is a contributing factor in the control of increased plasma IL-6 concentrations [76, 118]. Thus, therapeutic control of IL-6 with selective anti-cytokine interventions in combination with a standard treatment for uraemia is likely to improve many compounding complications associated with the clinical management of ESRD [112, 119, 120].

### INTERLEUKIN-6 AND CLINICAL OUTCOMES

It is widely acknowledged that cytokines play an integral role in determining the course of disease and IL-6 is increasing

<table>
<thead>
<tr>
<th>Factor</th>
<th>Condition</th>
<th>Associated outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6</td>
<td>AKI</td>
<td>Mortality</td>
<td>[10]</td>
</tr>
<tr>
<td></td>
<td>Ischaemia reperfusion injury</td>
<td>Unclear</td>
<td>[11]</td>
</tr>
<tr>
<td></td>
<td>Chronic allograft rejection</td>
<td>Acute rejection</td>
<td>[12]</td>
</tr>
<tr>
<td></td>
<td>Haemodialysis and peritoneal dialysis</td>
<td>Mortality</td>
<td>Pecoits-Filho et al. (2002) [17]</td>
</tr>
<tr>
<td>IL-6R</td>
<td>Haemodialysis and peritoneal dialysis</td>
<td>Malnutrition</td>
<td>[13, 14]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vascular changes</td>
<td>[15]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mortality</td>
<td>Pecoits-Filho et al. (2002) [17]</td>
</tr>
</tbody>
</table>

This table summarizes the published clinical and experimental studies linking the IL-6 pathway to renal disease, transplantation and renal replacement therapy, and its associated outcomes.
viewed as major drug targets for therapy (Figure 2). The application of biologics in conditions such as rheumatoid arthritis emphasize that early therapeutic intervention is essential to ensure appropriate management of the condition and potential disease remission [2]. While certain biologics (e.g. bevacizumab, a humanized monoclonal antibody to VEGF-A) have shown therapeutic efficacy in forms kidney cancer, their application in chronic renal diseases appears to have minimal appeal. This in part may reflect the success of renal transplantation. Instead, clinical assessments of cytokine expression or activities may be considered important prognostic or predictive biomarkers that forecast the course of disease and aid treatment decisions. For example, the monitoring of IL-6 in PD patients is providing valuable information on the loss of ultrafiltration capacity, fibrosis onset, the control of infection and treatment failures [17, 77, 79, 82, 83, 102]. Here, IL-6 activities not only predict local disease processes, but also provide valuable information on systemic inflammatory events and patient co-morbidities (Figure 2). For example, detection of serum IL-6 in PD patients significantly increases with time on dialysis and, as seen in other chronic diseases, correlates with indices of cardiovascular risk [121]. Such findings offer a valuable addition to the standard measurement of C-reactive protein and provide additional information on the potential efficiency of treatment. While the clinical assessment of C-reactive protein is used to reflect the degree of systemic inflammation and potential cardiovascular risk associated with a patient’s disease, the role of C-reactive protein in determining the underlying pathology is unclear [122]. Interleukin-6 is the principle driver of C-reactive protein expression and may be viewed as a surrogate marker of IL-6 bioactivity. In this context, the clinical assessment of IL-6 may provide a more powerful prediction of inflammation burden in ESRD [123, 124].

The impact of chronic kidney disease on healthcare systems around the world is increasing. In response, it is essential for new clinical assessments to be applied to provide a more personalized approach to patient stratification, and improvements in treatment decisions. Studies emphasize that IL-6 and associated downstream signalling events may represent one such marker (Figure 2). However to identify the pathways contributing to chronic disease progression in patients with varying degrees of renal disease, we must understand how cytokines like IL-6 govern acute resolving inflammation and how their activities become distorted to drive chronic inflammation.

REFERENCES


84. Hurst SM et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunology 2001; 114: 705–714.


111. Xu H et al. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int 2014


114. Pietrangelo A et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007; 132: 294–300

115. Nemeth E et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271–1276


125. Voorhees PM, Manges RF, Somlo G et al. A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM). J Clin Oncol 2009; 27 (Suppl. Abstr. 8527)

Received for publication: 13.1.2014; Accepted in revised form: 3.6.2014